Clinical, Anatomic, and Electrophyiologic Evaluation Following Intravitreal Bevacizumab for Macular Edema in Retinal Vein Occluion Original Reearch Article

Purpoe To invetigate clinical, anatomic, and electrophyiologic repone after ingle intravitreal injection of bevacizumab for macular edema attributable to retinal vein occluion. Deign Propective nonrandomized, interventional cae erie. Method Twenty-one patient with macular edema attributable to vein occluion received intravitreal injection of bevacizumab 1.25 mg. Nine patient had central retinal vein occluion (CRVO), and 12 patient had branch retinal vein occluion (BRVO). Complete ophthalmic examination including optical coherence tomography (OCT) wa done at baeline and follow-up viit. Fifteen patient underwent fluorecein angiography at baeline. elected patient underwent electroretinography (ERG) and viual evoked potential (VEP) at baeline and follow-up. Follow-up wa for 12 week. Reult At baeline, mean viual acuity wa 20/381 (median, 20/400) and howed improvement to mean 20/135 (median, 20/60) after one month, (P = .001). At 12 week, mean viual acuity wa 20/178 (median, 20/80) (P = .001). The mean central retinal thickne (CRT) wa 647.81 μm (median, 609.00 μm) at baeline and decreaed to mean 293.43 μm (median, 222.00 μm) at one month (P = .001). At 12 week, mean CRT wa 320.90 μm (median, 280.00 μm) (P = .001). ERG and VEP howed no worening of the waveform. There wa no ignificant difference in the viual outcome between the BRVO and CRVO group. Concluion Intravitreal injection of bevacizumab appear to reult in ignificant hort-term improvement of viual acuity and macular edema econdary to vein occluion. The preent report confirm the previou tudie. No ocular toxicity or advere effect were oberved. However, propective, randomized, controlled long-term tudie are required with an adequate number of patient.